Association between insulin receptor substrate 1 Gly972Arg polymorphism and cancer risk

被引:19
|
作者
Zhang, Hongtuan [1 ]
Wang, Andi [1 ,2 ]
Ma, Hui [3 ]
Xu, Yong [1 ,2 ]
机构
[1] Tianjin Med Univ, Affiliated Hosp 2, Tianjin Key Lab Urol, Natl Key Clin Specialty Urol, Tianjin 300211, Peoples R China
[2] Tianjin Key Lab Urol, Tianjin, Peoples R China
[3] Tianjin Med Univ, Affiliated Hosp 2, Dept Obstet & Gynaecol, Tianjin 300211, Peoples R China
关键词
Insulin receptor substrate 1; Polymorphism; Cancer; Meta-analysis; Association; GROWTH-FACTOR-I; COLORECTAL-CANCER; BREAST-CANCER; PROSTATE-CANCER; GENETIC POLYMORPHISMS; NO ASSOCIATION; RECTAL-CANCER; UNITED-STATES; IRS1; SUSCEPTIBILITY;
D O I
10.1007/s13277-013-0855-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epidemiological studies investigating the association between the insulin receptor substrate 1 (IRS1) gene Gly972Arg (rs1801278) polymorphism and various carcinomas risk reported conflicting results. Thus, a systemic review and meta-analysis of published studies were performed to assess the possible association. A comprehensive search was conducted to identify all eligible studies of IRS1 Gly972Arg polymorphism and cancer risk. Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the strength of the associations. A total of 16 independent studies, including 11,776 cases and 11,654 controls, were identified. When all studies were pooled, we found a significant association between IRS1 Gly972Arg polymorphism and increased cancer risk under dominant model (OR = 1.16, 95 %CI = 1.04-1.30, P = 0.007) and allelic model (OR = 1.16, 95 %CI = 1.02-1.30, P = 0.02). In subgroup analysis based on cancer type, increased cancer risk was found in ovarian cancer (dominant: OR = 1.55, 95 %CI = 1.17-2.05, P = 0.002; allelic: OR = 1.55, 95 %CI = 1.19-2.01, P = 0.001), breast cancer (allelic: OR = 1.12, 95 %CI = 1.00-1.26, P = 0.05), and other cancers (allelic: OR = 1.31, 95 %CI = 1.00-1.71, P = 0.05). When stratified by study types, significant associations were observed in both cohort studies (dominant: OR = 1.25, 95 %CI = 1.06-1.47, P = 0.007; allelic: OR = 1.25, 95 %CI = 1.07-1.46, P = 0.005) and case-control studies (dominant: OR = 1.15, 95 %CI = 1.01-1.31, P = 0.04). In the subgroup analyses by ethnicity, significantly increased cancer risk was suggested among both Caucasians (dominant: OR = 1.13, 95 %CI = 1.02-1.26, P = 0.02; allelic: OR = 1.13, 95 %CI = 1.03-1.25, P = 0.01) and mixed population (dominant: OR = 1.22, 95 %CI = 1.01-1.46, P = 0.04). Our investigations demonstrate that IRS1 Gly972Arg polymorphism was associated with an increased risk of cancer, and additional well-designed studies are warranted to validate these findings.
引用
收藏
页码:2929 / 2936
页数:8
相关论文
共 50 条
  • [21] The insulin receptor substrate-1 Gly972Arg polymorphism is not associated with Type 2 diabetes mellitus in two population-based studies
    van Dam, RM
    Hoebee, B
    Seidell, JC
    Schaap, MM
    Blaak, EE
    Feskens, EJM
    DIABETIC MEDICINE, 2004, 21 (07) : 752 - 758
  • [22] Interaction effect between common polymorphisms in PPARγ2 (Pro12Ala) and insulin receptor substrate 1 (Gly972Arg) on insulin sensitivity
    Michael Stumvoll
    Norbert Stefan
    Andreas Fritsche
    Alexander Madaus
    Otto Tschritter
    Matthias Koch
    Fausto Machicao
    Hans Häring
    Journal of Molecular Medicine, 2002, 80 : 33 - 38
  • [23] Relationship between Gly972Arg Variant of Insulin Receptor Substrate-1 Gene and Endothelial Dysfunction Measured by Flow Mediated Dilation
    Wulandari, P.
    Sukmawan, R.
    Sunu, I.
    Supari, S. F.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2018, 20 (0D) : D21 - D21
  • [24] Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes:: a meta-analysis of 27 studies
    Jellema, A
    Zeegers, MPA
    Feskens, EJM
    Dagnelie, PC
    Mensink, RP
    DIABETOLOGIA, 2003, 46 (07) : 990 - 995
  • [25] Interaction effect between common polymorphisms in PPARγ2 (Pro12Ala) and insulin receptor substrate 1 (Gly972Arg) on insulin sensitivity
    Stumvoll, M
    Stefan, N
    Fritsche, A
    Madaus, A
    Tschritter, O
    Koch, M
    Machicao, F
    Häring, H
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2002, 80 (01): : 33 - 38
  • [26] Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies
    A. Jellema
    M. P. A. Zeegers
    E. J. M. Feskens
    P. C. Dagnelie
    R. P. Mensink
    Diabetologia, 2003, 46 : 990 - 995
  • [27] FREQUENCY OF DISTRIBUTION OF INSULIN RESISTANCE IN PATIENTS WITH ESSENTIAL ARTERIAL HYPERTENSION AND GLY972ARG POLYMORPHISM OF THE INSULIN RECEPTOR SUBSTRATE-1 GENE IN RELATION TO DIFFERENT DIETARY SODIUM INTAKE
    Porzezinska, J.
    Dziwura, J.
    Brzeska, A.
    Binczak-Kuleta, A.
    Widecka, K.
    JOURNAL OF HYPERTENSION, 2009, 27 : S256 - S256
  • [28] Lack of association between the insulin receptor substrates-1 Gly972Arg polymorphism and type-2 diabetes mellitus among Saudis from Eastern Saudi Arabia
    Alsalman, Hawra A.
    Kaabi, Yahia A.
    SAUDI MEDICAL JOURNAL, 2015, 36 (12) : 1420 - 1424
  • [29] Arg972 insulin receptor substrate-1 polymorphism and risk and severity of rheumatoid arthritis
    Zhao, Hongjun
    Liu, Shiqing
    Long, Mei
    Peng, Lijuan
    Deng, Hongxiang
    You, Yunhui
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (02) : 141 - 145
  • [30] Intima media thickness of carotid arteries is reduced in heterozygous carriers of the Gly972Arg variant in the insulin receptor substrate-1 gene
    Hölzl, B
    Iglseder, B
    Stadlmayr, A
    Hedegger, M
    Moré, E
    Reiter, R
    Sandhofer, F
    Paulweber, B
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (02) : 110 - 116